SCHEMBL6233916

SCHEMBL6233916

CC(=O)OCCCCCCn1ccc2cc([N+](=O)[O-])ccc21

nearest known ligand 0.67

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
KRAS P01116 1/20 0.42
PLG P00747 1/20 0.41
PLAU P00749 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31735444 0.91 MEN1 (0.46) MEN1KMT2AKRASPLGPLAU
SCHEMBL6230447 0.82 PLG (0.46) KRASPLGPLAU
SCHEMBL27732822 0.81 HTR7 (0.54) MEN1KMT2A
SCHEMBL7928062 0.81 ALOX5 (0.47) MEN1KMT2AKRASPLGPLAU
SCHEMBL6235981 0.80 LMNA (0.49) MEN1KMT2A
SCHEMBL7921048 0.80 KRAS (0.47) KRASPLGPLAU
SCHEMBL14041459 0.80 MTNR1A (0.56)
SCHEMBL2479169 0.79 HTR7 (0.47) KRASPLGPLAU
SCHEMBL2124040 0.78 PLG (0.46) KMT2AKRASPLGPLAU
SCHEMBL30672858 0.78 PLG (0.46) KMT2AKRASPLGPLAU

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005002337-A1 DISINFECTANT COMPOSITIONS AND METHODS VIRTUAL DRUG DEVELOPMENT, INC. (US) 2005-01-13 WO disclosed
EP-1047692-B1 METHODS OF SYNTHESIZING AND SCREENING INHIBITORS OF BACTERIAL NAD SYNTHETASE ENZYME, COMPOUNDS THEREOF AND METHODS OF TREATING BACTERIAL AND MICROBIAL INFECTIONS WITH THESE INHIBITORS UAB RESEARCH FOUNDATION (US) 2004-07-21 EP disclosed
US-6727237-B2 Inhibitors of bacterial NAD synthetase BROUILLETTE WAYNE J (US) 2004-04-27 US disclosed
US-20040063758-A1 INHIBITORS OF BACTERIAL NAD SYNTHETASE BROUILLETTE WAYNE J (US) 2004-04-01 US disclosed
US-6500852-B1 ENZYME INHIBITORS OF BACTERIAL NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) ENZYME LYASES USED AS BACTERICIDES, MICROBIOCIDE, ANTISEPTICS OR ANTIBIOTICS UNIVERSITY OF ALABAMA RESEARCH FOUNDATION 2002-12-31 US disclosed
EP-1047692-A1 METHODS OF SYNTHESIZING AND SCREENING INHIBITORS OF BACTERIAL NAD SYNTHETASE ENZYME, COMPOUNDS THEREOF AND METHODS OF TREATING BACTERIAL AND MICROBIAL INFECTIONS WITH THESE INHIBITORS THE UAB RESEARCH FOUNDATION (US) 2000-11-02 EP disclosed
WO-1999036422-A1 METHODS OF SYNTHESIZING AND SCREENING INHIBITORS OF BACTERIAL NAD SYNTHETASE ENZYME, COMPOUNDS THEREOF, AND METHODS OF TREATING BACTERIAL AND MICROBIAL INFECTIONS WITH INHIBITORS OF BACTERIAL NAD SYNTHETASE ENZYME THE UAB RESEARCH FOUNDATION (US) 1999-07-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063758-A1 INHIBITORS OF BACTERIAL NAD SYNTHETASE COASY, NADK, NQO1 MEN1 3777/4885KMT2A 2077/4885KRAS 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.